Paul Bunn, MD
Distinguished Professor, Medicine-Medical Oncology

Photo
Download CV
Medical School:
  • MD, Weill Cornell Medical College (1971)
Undergraduate School:
  • BA, Amherst College (MA) (1967)
Internship:
  • University of California (San Francisco) Program (1972)
Residency:
  • University of California (San Francisco) Program, Internal Medicine (1973)
Fellowships:
  • National Cancer Institute, Medical Oncology (1975)
Languages: English
Department: Medicine-Medical Oncology

Professional Titles

  • James Dudley Chair in Cancer Research

Recognition & Awards

  • The 400 Best Doctors in America, Good Housekeeping (2019)
  • America's Top Doctors for Cancer, Castle Connolly Medical Ltd. (2019)
  • Honoary Membership, Hungarian Respiratory Society (2018)
  • ASCO Karnofsky Award, ASCO (2016)
  • Lung Cancer Network Award for Distinguished Education and Research, University of Athens (2016)
  • Giants in Cancer Care Award, OncLive (2016)

Research Interests

Dr. Bunn's lab conducts studies on the development of novel growth factor inhibitors for chemoprevention and the treatment of lung cancer. Dr. Bunn is involved in clinical trials of novel molecular therapies and immunotherapies for lung cancer.

Teaching

  • Professor (1984)
    School of Medicine, Medicine

Publications

  • Schenk EL, Patil T, Pacheco J, Bunn PA Jr. 2020 Innovation Based Optimism for Lung Cancer Outcomes. Oncologist. 2020 Nov 11. [Epub ahead of print] PubMed PMID: 33179378
  • Bunn PA Jr. How gradual retirement has allowed me to spend more time with family and being physically active. Clin Adv Hematol Oncol. 2020 Jan;18(1):17-18. PubMed PMID: 32511217
  • Patil T, Pacheco JM, Dimou A, Purcell WT, Rossi C, Bunn PA, Doebele RC, Camidge DR, Ferrigno L. Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR -Mutant Non-small Cell Lung Cancer. Front Oncol. 2020;10:510. PubMed PMID: 32351892
  • Boyle TA, Khalil FK, Mino-Kenudson M, Sica GL, Moreira AL, Sholl LM, Knight MZ, Zhang L, Saller J, Varella-Garcia M, Berry LD, Chen H, Ellison KE, Rivard CJ, Kugler K, Wistuba II, Fujimoto J, Kwiatkowski DJ, Bunn PA, Kris MG, Haura EB, Hirsch FR. Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance. Appl Immunohistochem Mol Morphol. 2020 Oct;28(9):669-677. PubMed PMID: 31876606
  • Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 May;21(3):e191-e204. PubMed PMID: 31859066
  • Boyle TA, Khalil FK, Mino-Kenudson M, Sica GL, Moreira AL, Sholl LM, Knight MZ, Zhang L, Saller J, Varella-Garcia M, Berry LD, Chen H, Ellison KE, Rivard CJ, Kugler K, Wistuba II, Fujimoto J, Kwiatkowski DJ, Bunn PA, Kris MG, Haura EB, Hirsch FR. Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance. Appl Immunohistochem Mol Morphol. 2019 Nov 22. [Epub ahead of print] PubMed PMID: 31876606
  • Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2019 Nov 21. [Epub ahead of print] PubMed PMID: 31859066
  • Mulshine JL, Ujhazy P, Antman M, Burgess CM, Kuzmin I, Bunn PA Jr, Johnson BE, Roth JA, Pass HI, Ross SM, Aldige CR, Wistuba II, Minna JD. From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. J Cell Biochem. 2019 Dec 5. [Epub ahead of print] PubMed PMID: 31803961
  • Keith RL, Blatchford PJ, Merrick DT, Bunn PA Jr, Bagwell B, Dwyer-Nield LD, Jackson MK, Geraci MW, Miller YE. A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers. Cancer Prev Res (Phila). 2019 Oct;12(10):721-730. PubMed PMID: 31308004
  • Guo R, Berry LD, Aisner DL, Sheren J, Boyle T, Bunn PA Jr, Johnson BE, Kwiatkowski DJ, Drilon A, Sholl LM, Kris MG. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. J Thorac Oncol. 2019 Sep;14(9):1666-1671. PubMed PMID: 31228623
  • Bunn PA Jr, Schenk E, Pacheco J, Dimou A. New Developments in Neoadjuvant Therapy for Lung Cancer. Oncology (Williston Park). 2019 Mar 13;33(3):101-6, 109. PubMed PMID: 30866032
  • El Osta B, Behera M, Kim S, Berry LD, Sica G, Pillai RN, Owonikoko TK, Kris MG, Johnson BE, Kwiatkowski DJ, Sholl LM, Aisner DL, Bunn PA, Khuri FR, Ramalingam SS. Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2019 May;14(5):876-889. PubMed PMID: 30735816
  • Pacheco J, Bunn PA. Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133. Clin Lung Cancer. 2019 May;20(3):148-160.e2. PubMed PMID: 30686680
  • Mulshine JL, Ujhazy P, Antman M, Burgess CM, Kuzmin I, Bunn PA Jr, Johnson BE, Roth JA, Pass HI, Ross SM, Aldige CR, Wistuba II, Minna JD. From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. J Cell Biochem. 2019 Dec 5. [Epub ahead of print] PubMed PMID: 31803961
  • Keith RL, Blatchford PJ, Merrick DT, Bunn PA Jr, Bagwell B, Dwyer-Nield LD, Jackson MK, Geraci MW, Miller YE. A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers. Cancer Prev Res (Phila). 2019 Oct;12(10):721-730. PubMed PMID: 31308004
  • Guo R, Berry LD, Aisner DL, Sheren J, Boyle T, Bunn PA Jr, Johnson BE, Kwiatkowski DJ, Drilon A, Sholl LM, Kris MG. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. J Thorac Oncol. 2019 Sep;14(9):1666-1671. PubMed PMID: 31228623
  • Bunn PA Jr, Schenk E, Pacheco J, Dimou A. New Developments in Neoadjuvant Therapy for Lung Cancer. Oncology (Williston Park). 2019 Mar 13;33(3):101-6, 109. PubMed PMID: 30866032
  • El Osta B, Behera M, Kim S, Berry LD, Sica G, Pillai RN, Owonikoko TK, Kris MG, Johnson BE, Kwiatkowski DJ, Sholl LM, Aisner DL, Bunn PA, Khuri FR, Ramalingam SS. Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2019 May;14(5):876-889. PubMed PMID: 30735816
  • Pacheco J, Bunn PA. Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133. Clin Lung Cancer. 2019 May;20(3):148-160.e2. PubMed PMID: 30686680
  • Noonan SA, Patil T, Gao D, King GG, Thibault JR, Lu X, Bunn PA, Doebele RC, Purcell WT, Barón AE, Camidge DR. Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol. 2018 Jan;13(1):134-138. PubMed PMID: 28843358
  • Pacheco JM, Gao D, Smith D, Purcell WT, Hancock M, Bunn PA, Robin TP, Liu AK, Karam S, Gaspar LE, Kavanagh BD, Rusthoven CG, Aisner DL, Doebele RC, Camidge DR. Natural history and factors associated with overall survival in stage IV ALK rearranged non-small-cell lung cancer. J Thorac Oncol. 2018 Dec 29. [Epub ahead of print] PubMed PMID: 30599201
  • Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol. 2018 Dec;13(12):1818-1831. PubMed PMID: 30268698
  • Bunn PA Jr, Aisner DL. Broad-Based Molecular Testing for Lung Cancer: Precisely the Time for Precision. JAMA. 2018 Aug 7;320(5):445-446. PubMed PMID: 30087992
  • Bunn PA Jr, Dimou A. Systemic Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancers. J Clin Oncol. 2018 Sep 1;36(25):2571-2574. PubMed PMID: 30028655
  • Merrick DT, Edwards MG, Franklin WA, Sugita M, Keith RL, Miller YE, Friedman MB, Dwyer-Nield LD, Tennis MA, O'Keefe MC, Donald EJ, Malloy JM, van Bokhoven A, Wilson S, Koch PJ, O'Shea C, Coldren C, Orlicky DJ, Lu X, Baron AE, Hickey G, Kennedy TC, Powell R, Heasley L, Bunn PA, Geraci M, Nemenoff RA. Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res. 2018 Sep 1;78(17):4971-4983. PubMed PMID: 29997230
  • Patil T, Smith DE, Bunn PA, Aisner DL, Le AT, Hancock M, Purcell WT, Bowles DW, Camidge DR, Doebele RC. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol. 2018 Nov;13(11):1717-1726. PubMed PMID: 29981925
  • Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA Jr, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, Pérol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol. 2018 Aug 1;29(8):1701-1709. PubMed PMID: 29905778
  • Hirsch FR, Kerr KM, Bunn PA Jr, Kim ES, Obasaju C, Pérol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N. Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. Clin Lung Cancer. 2018 Jul;19(4):331-339. PubMed PMID: 29773328
  • He Y, Liu S, Mattei J, Bunn PA Jr, Zhou C, Chan D. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. Drug Des Devel Ther. 2018;12:981-986. PubMed PMID: 29731605
  • McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA Jr, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC. Resistance Mechanisms to Targeted Therapies in ROS1 ( ) and ALK ( ) Non-small Cell Lung Cancer. Clin Cancer Res. 2018 Jul 15;24(14):3334-3347. PubMed PMID: 29636358
  • Hirsch FR, Sequist LV, Gore I, Mooradian M, Simon G, Croft EF, DeVincenzo D, Munley J, Stein D, Freivogel K, Sifakis F, Bunn PA Jr. Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP). Cancer. 2018 Jun 1;124(11):2407-2414. PubMed PMID: 29579334
  • Helfrich BA, Gao D, Bunn PA Jr. Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. Lung Cancer. 2018 Apr;118:148-154. PubMed PMID: 29571994
  • Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2018 Mar 1;24(5):1038-1047. PubMed PMID: 29217530
  • Noonan SA, Patil T, Gao D, King GG, Thibault JR, Lu X, Bunn PA, Doebele RC, Purcell WT, Barón AE, Camidge DR. Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol. 2018 Jan;13(1):134-138. PubMed PMID: 28843358
  • Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA Jr, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Wakelee H, Thatcher N. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. J Thorac Oncol. 2018 Feb;13(2):165-183. PubMed PMID: 29175116
  • Paz-Ares LG, Zimmermann A, Ciuleanu T, Bunn PA, Antonio BS, Denne J, Iturria N, John W, Scagliotti GV. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer. 2017 Feb;104:45-51. PubMed PMID: 28212999
  • Bunn PA Jr. Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. J Clin Oncol. 2017 Jan 10;35(2):243-252. PubMed PMID: 28056194
  • Suda K, Bunn PA Jr, Rivard CJ, Mitsudomi T, Hirsch FR. Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench. J Thorac Oncol. 2017 Jan;12(1):27-35. PubMed PMID: 27642065
  • Aisner DL, Sholl LM, Berry L, Rossi M, Chen H, Fujimoto J, Moreira AL, Ramalingam S, Villaruz LC, Otterson GA, Haura EB, Politi K, Glisson BS, Cetnar J, Garon E, Schiller J, Waqar S, Sequist LV, Brahmer JR, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ. The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2017 Dec 7. [Epub ahead of print] PubMed PMID: 29217530
  • Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017 Nov 10;17(12):765. [Epub ahead of print] PubMed PMID: 29123245
  • Pacheco JM, Dimou A, Bunn PA. Advances in lung cancer. Oncotarget. 2017 Oct 3;8(45):78247-78248. PubMed PMID: 29108218
  • Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017 Dec;17(12):725-737. PubMed PMID: 29077690
  • Leonard SC, Lee H, Gaddy DF, Klinz SG, Paz N, Kalra AV, Drummond DC, Chan DC, Bunn PA, Fitzgerald JB, Hendriks BS. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. Anticancer Drugs. 2017 Nov;28(10):1086-1096. PubMed PMID: 28857767
  • Bunn PA Jr. Robert Comis, MD, The Passing of a "Lung Man". J Thorac Oncol. 2017 Aug;12(8):1323-1324. PubMed PMID: 28748814
  • Pillai RN, Behera M, Berry LD, Rossi MR, Kris MG, Johnson BE, Bunn PA, Ramalingam SS, Khuri FR. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer. 2017 Nov 1;123(21):4099-4105. PubMed PMID: 28743157
  • Paz-Ares LG, Zimmermann A, Ciuleanu T, Bunn PA, Antonio BS, Denne J, Iturria N, John W, Scagliotti GV. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer. 2017 Feb;104:45-51. PubMed PMID: 28212999
  • Bunn PA Jr. Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. J Clin Oncol. 2017 Jan 10;35(2):243-252. PubMed PMID: 28056194
  • Scarborough HA, Helfrich BA, Casás-Selves M, Schuller AG, Grosskurth SE, Kim J, Tan AC, Chan DC, Zhang Z, Zaberezhnyy V, Bunn PA, DeGregori J. AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. Clin Cancer Res. 2017 Mar 15;23(6):1531-1541. PubMed PMID: 27663586
  • Suda K, Bunn PA Jr, Rivard CJ, Mitsudomi T, Hirsch FR. Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench. J Thorac Oncol. 2017 Jan;12(1):27-35. PubMed PMID: 27642065
  • He Y, Bunn PA, Zhou C, Chan D. KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer. Oncotarget. 2016 Dec 13;7(50):82104-82111. PubMed PMID: 27893413
  • Scarborough HA, Helfrich BA, Casás-Selves M, Schuller AG, Grosskurth SE, Kim J, Tan AC, Chan DC, Zhang Z, Zaberezhnyy V, Bunn PA, DeGregori J. AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. Clin Cancer Res. 2016 Sep 23. [Epub ahead of print] PubMed PMID: 27663586
  • Hirsch FR, Suda K, Wiens J, Bunn PA Jr. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016 Sep 3;388(10048):1012-24. PubMed PMID: 27598681
  • Helfrich BA, Kim J, Gao D, Chan DC, Zhang Z, Tan AC, Bunn PA Jr. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther. 2016 Oct;15(10):2314-2322. PubMed PMID: 27496133
  • Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA Jr, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol. 2016 Jul;11(7):946-63. PubMed PMID: 27229180
  • Patil T, Aisner DL, Noonan SA, Bunn PA, Purcell WT, Carr LL, Camidge DR, Doebele RC. Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. Lung Cancer. 2016 Jun;96:27-32. PubMed PMID: 27133746
  • Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016 May;11(5):613-38. PubMed PMID: 27013409
  • Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. J Thorac Oncol. 2016 Apr;11(4):453-74. PubMed PMID: 26829312
  • Bunn PA Jr, Gaspar LE, Weyant MJ, Mitchell JD. Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer. Cancer. 2016 Mar 1;122(5):674-5. PubMed PMID: 26700372
  • Steuer CE, Behera M, Berry L, Kim S, Rossi M, Sica G, Owonikoko TK, Johnson BE, Kris MG, Bunn PA, Khuri FR, Garon EB, Ramalingam SS. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer. 2016 Mar 1;122(5):766-72. PubMed PMID: 26695526
  • Merrick DT, Gao D, Miller YE, Keith RL, Baron AE, Feser W, Kennedy TC, Blatchford PJ, Braudrick S, Hirsch FR, Heasley L, Bunn PA Jr, Franklin WA. Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma. Cancer Prev Res (Phila). 2016 Jan;9(1):96-104. PubMed PMID: 26542061
  • Hirsch FR, Bunn PA Jr. Progress in research on screening and genetics in lung cancer. Lancet Respir Med. 2014 Jan;2(1):19-21. PubMed PMID: 24461890
  • Scarborough HA, Bunn PA Jr, DeGregori J. Personalized one-two punches for lung cancer. Cell Res. 2014 Dec 30. [Epub ahead of print] PubMed PMID: 25547118
  • Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R. Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 2014 Dec 1;32(34):3824-30. PubMed PMID: 25349291
  • Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer. 2014 Oct 1. [Epub ahead of print] PubMed PMID: 25273224
  • Johnson DH, Schiller JH, Bunn PA. Reply to A. Braillon. J Clin Oncol. 2014 Nov 1;32(31):3575. PubMed PMID: 25225428
  • Hirsch FR, Bunn PA Jr, Herbst RS. "Companion diagnostics": has their time come and gone?. Clin Cancer Res. 2014 Sep 1;20(17):4422-4. PubMed PMID: 25059519
  • Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 May 21;311(19):1998-2006. PubMed PMID: 24846037
  • Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA Jr, Camidge DR, Tan AC, Hirsch FR, Heasley LE. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res. 2014 Jun 15;20(12):3299-309. PubMed PMID: 24771645
  • Bunn PA Jr, Hirsch FR, Aisner DL. Is there clinical value to prognostic signatures in early-stage NSCLC?. Clin Cancer Res. 2014 Apr 1;20(7):1727-9. PubMed PMID: 24583801
  • Johnson DH, Schiller JH, Bunn PA Jr. Recent clinical advances in lung cancer management. J Clin Oncol. 2014 Apr 1;32(10):973-82. PubMed PMID: 24567433
  • Hirsch FR, Bunn PA Jr. Progress in research on screening and genetics in lung cancer. Lancet Respir Med. 2014 Jan;2(1):19-21. PubMed PMID: 24461890
  • Peled N, Zach L, Liran O, Ilouze M, Bunn PA Jr, Hirsch FR. Effective Crizotinib Schedule for Brain Metastases in ALK Rearrangement Metastatic Non-Small-Cell Lung Cancer. J Thorac Oncol. 2013 Dec;8(12):e112-3. PubMed PMID: 24389447
  • Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA Jr, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC. Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer. PLoS One. 2013;8(12):e82236. PubMed PMID: 24349229
  • Bunn PA Jr, Franklin W, Doebele RC. The evolution of tumor classification: a role for genomics?. Cancer Cell. 2013 Dec 9;24(6):693-4. PubMed PMID: 24332038
  • Shepherd FA, Bunn PA, Paz-Ares L. Lung cancer in 2013: state of the art therapy for metastatic disease. Am Soc Clin Oncol Educ Book. 2013;33:339-46. PubMed PMID: 23714542
  • Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok T, Popat S, Bauman J, Nieva J, Novello S, Ou SH, Camidge DR. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer. 2013 Jul 1;119(13):2383-90. PubMed PMID: 23585220
  • Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA Jr, Pao W. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res. 2013 May 1;19(9):2584-91. PubMed PMID: 23515407
  • Peled N, Barash O, Tisch U, Ionescu R, Broza YY, Ilouze M, Mattei J, Bunn PA Jr, Hirsch FR, Haick H. Volatile fingerprints of cancer specific genetic mutations. Nanomedicine. 2013 Aug;9(6):758-66. PubMed PMID: 23428987
  • Mascaux C, Feser WJ, Lewis MT, Barón AE, Coldren CD, Merrick DT, Kennedy TC, Eckelberger JI, Rozeboom LM, Franklin WA, Minna JD, Bunn PA, Miller YE, Keith RL, Hirsch FR. Endobronchial miRNAs as biomarkers in lung cancer chemoprevention. Cancer Prev Res (Phila). 2013 Feb;6(2):100-8. PubMed PMID: 23268837
View All (79 Total) View Less

Professional Memberships

  • American Association for Cancer Research, Member
  • American Society of Clinical Oncology, Fellow
  • International Association for Study of Lung Cancer, Member
  • American Association for Advancement of Science, Member
  • Westerm Association of Physicians, Member
  • Southwest Oncology Group, Member
  • American College of Physicians (ACP), Member

Practice Locations

University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

Valley View Hospital Cancer Center
1906 Blake Ave.
Glenwood Springs, CO 81601
970-384-7570

Lung Cancer Clinic - Anschutz
1665 Aurora Ct
Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-0300

UCH - Cancer Center
1665 Aurora Ct
Aurora, CO 80045
720-848-0300

Hospital Affiliation
  • University of Colorado Hospital
Center Affiliations

Specialty Information

Specialties
  • Internal Medicine, Board Certification (1974)
  • Medical Oncology, Board Certification (1975)
Conditions & Treatments
  • Cancers - Lung Cancer
  • Cancers
  • Cancers - Thoracic (Tracheal, Esophageal)
Personal Interests
Outside of work, I enjoy skiing, tennis, hiking, and biking.

General Information

Medical Schools:
  • MD, Weill Cornell Medical College (1971)
Undergraduate Schools:
  • BA, Amherst College (MA) (1967)
Internships:
  • University of California (San Francisco) Program (1972)
Residency Programs:
  • University of California (San Francisco) Program, Internal Medicine (1973)
Fellowships:
  • National Cancer Institute, Medical Oncology (1975)
Download CV
Languages: English
Department: Medicine-Medical Oncology
;